Literature DB >> 11550304

Chemotherapy for brain tumors of astrocytic and oligodendroglial lineage: the past decade and where we are heading.

V A Levin1.   

Abstract

Over the past three decades, we have made great strides in the treatment of most, but not all, brain tumors. Dramatic advances have occurred in diagnostic imaging, neurosurgery, neuroanesthesia, radiotherapy, and chemotherapy for CNS tumors. Unfortunately, our progress has not yet met our expectations. Because of the infiltrative nature of most primary brain tumors, neurosurgery can never be expected to be curative for the majority of gliomas. Because infiltrative tumors interdigitate with normal brain cells and are not highly sensitive to irradiation, one cannot expect radiotherapy to be curative without serious damage to normal brain cells. The hope for a cure, then, rests with chemotherapy. Those who administer chemotherapy to patients with CNS tumors fully expect that, in time, long-term survival and, ultimately, the cure will become an everyday reality. To achieve that reality, however, new treatment concepts and drugs are needed.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 11550304      PMCID: PMC1919464          DOI: 10.1093/neuonc/1.1.69

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  8 in total

Review 1.  Paediatric and adult malignant glioma: close relatives or distant cousins?

Authors:  Chris Jones; Lara Perryman; Darren Hargrave
Journal:  Nat Rev Clin Oncol       Date:  2012-05-29       Impact factor: 66.675

2.  Subventricular zone involvement at recurrence is a strong predictive factor of outcome following high grade glioma reirradiation.

Authors:  J Attal; L Chaltiel; V Lubrano; J C Sol; C Lanaspeze; L Vieillevigne; I Latorzeff; E Cohen-Jonathan Moyal
Journal:  J Neurooncol       Date:  2017-12-22       Impact factor: 4.130

3.  Phase II study of temozolomide and cisplatin as primary treatment prior to radiotherapy in newly diagnosed glioblastoma multiforme patients with measurable disease. A study of the Spanish Medical Neuro-Oncology Group (GENOM).

Authors:  Carmen Balaña; Antonio López-Pousa; Alfonso Berrocal; Ricardo Yaya-Tur; Ana Herrero; Jose-Luis García; Javier Martín-Broto; Manuel Benavides; Miguel Cerdá-Nicolás; Rosa Ballester; Josep Balart; Jaume Capellades
Journal:  J Neurooncol       Date:  2004-12       Impact factor: 4.130

4.  Ligands for PPARgamma and RAR cause induction of growth inhibition and apoptosis in human glioblastomas.

Authors:  Chuanbing Zang; Marlies Wächter; Hongyu Liu; Maximilian G Posch; Martin H Fenner; Christine Stadelmann; Andreas von Deimling; Kurt Possinger; Keith L Black; H Phillip Koeffler; Elena Elstner
Journal:  J Neurooncol       Date:  2003-11       Impact factor: 4.130

5.  Use of 201Tl SPECT imaging to assess the response to therapy in patients with high grade gliomas.

Authors:  V Vallejos; C Balaña; M Fraile; Y Roussos; J Capellades; P Cuadras; R Ballester; A Ley; A Arellano; R Rosell
Journal:  J Neurooncol       Date:  2002-08       Impact factor: 4.130

6.  Phase 2 study of temozolomide and Caelyx in patients with recurrent glioblastoma multiforme.

Authors:  Susan L Chua; Mark A Rosenthal; Shirley S Wong; David M Ashley; Anne-Marie Woods; Anthony Dowling; Lawrence M Cher
Journal:  Neuro Oncol       Date:  2004-01       Impact factor: 12.300

7.  The Treatment of Malignant Gliomas.

Authors:  Mark R Gilbert; Monica Loghin
Journal:  Curr Treat Options Neurol       Date:  2005-07       Impact factor: 3.972

8.  Therapeutic effects of Holmium-166 chitosan complex in rat brain tumor model.

Authors:  Ryoong Huh; Yong Sook Park; Jong Doo Lee; Young Sun Chung; Yong Gou Park; Sang Sup Chung; Jin Woo Chang
Journal:  Yonsei Med J       Date:  2005-02-28       Impact factor: 2.759

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.